Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis because it is
often detected at an advanced stage, and drug resistance interferes with treatment …

Introduction Gemcitabine is an important component of pancreatic cancer clinical
management. Unfortunately, acquired gemcitabine resistance is widespread and there are …

Introduction: Pancreatic cancer has the worst survival rate of all cancers. The current
standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this …

The prognosis of pancreatic cancer remains poor, and the standard first-line chemotherapy
with gemcitabine (GEM) has a response rate of less than 20%. Since expression of …

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest incidence/death ratios
among all neoplasms due to its late diagnosis and dominant chemoresistance. Most PDAC …

Gemcitabine (GEM) alone and GEM‐based chemotherapy are the preferred regimens for
treating advanced unresectable and metastatic pancreatic cancer (PC). However, these …

Background Profound resistance to chemotherapy remains a major challenge in achieving
better clinical outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). Recent …

Gemcitabine is currently the leading therapeutic for pancreatic cancer treatment, despite
growing resistance. Studying the mechanisms that underlie gemcitabine resistance and …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the
United States. The deoxynucleoside analogue gemcitabine is among the most effective …

Most human cancers display high levels of heterogeneity, a feature that often impacts
negatively on the response to treatments. Indeed, while radio and/or chemotherapy initially …